Rights and permissions
About this article
Cite this article
Immunochemotherapy using picibanil offers a survival benefit over chemotherapy alone in NSCLC. Inpharma Wkly. 1299, 14 (2001). https://doi.org/10.2165/00128413-200112990-00035
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200112990-00035